Company intelligence / Profile preview

Leapfrog Bio

San Mateo, California, USAleapfrog.bio ↗

Ownership: Private
Development stage: Phase 2

Overview

Leapfrog Bio’s lead candidate LFB190 targets solid tumors with EP300 loss-of-function mutations using a BET inhibitor. The compound is Phase 2-ready for lung, bladder, and colon cancers. Their platform has shown strong retrospective validation in real-world data analyses and preclinical models. Clinical trials are expected to begin in 2025 for LFB190; additional candidates are advancing toward the clinic.

Therapeutic areas: Oncology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

3 assets

LFB101

Preclinical

2 more assets in the full pipeline.

Request access →

Partnerships

Leapfrog works with pharmaceutical/biotech companies to retarget shelved product candidates for new oncology indications but no specific partners have been publicly disclosed as of May 2025.

Beyond the preview

Go deeper on Leapfrog Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Leapfrog Bio.

Explore the full profile